Editorial: Can lipid abnormalities predict renal disease in patients with diabetes?

Clinical Lipidology

Volumn 5, Issue 2, 2010, Pages 151-155

  Tolonen, Nina E ^a   Groop, Per Henrik ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENTIATION; DYSLIPIDEMIA; EDITORIAL; GLOMERULOSCLEROSIS; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LOSS OF FUNCTION MUTATION; MICROALBUMINURIA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REFERENCE VALUE; RISK REDUCTION; SECONDARY PREVENTION;

EID: 77950191300     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.1     Document Type: Editorial

References (49)

1. Groop PH, Thomas MC, Moran JL et al.: The presence and severity of chronic kidney disease predicts all-cause mortality in Type 1 diabetes. Diabetes 58, 1651-1658 (2009).
2. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 281, 1291-1297 (1999).
3. Borch-Johnsen K, Kreiner S: Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 294, 1651-1654 (1987).
4. Tolonen N, Forsblom C, Thorn L et al.: Relationship between lipid profiles and kidney function in patients with Type 1 diabetes. Diabetologia 51, 12-20 (2008).
5. Groop PH, Elliott T, Ekstrand A et al.: Multiple lipoprotein abnormalities in Type I diabetic patients with renal disease. Diabetes 45, 974-979 (1996).
6. Idzior-Walus B, Mattock MB, Solnica B, Stevens L, Fuller JH; EURODIAB IDDM Complications Study Group: Factors associated with plasma lipids and lipoproteins in Type 1 diabetes mellitus: The EURODIAB IDDM complications study. Diabetic Med. 18, 786-796 (2001).
7. Olivarius NF, Andreasen AH, Keiding N, Mogensen CE: Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark. Diabetologia 36, 1007-1016 (1993).
8. Vaziri ND: Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 63, 1964-1976 (2003).
9. Myhre E, Gjone E, Flatmark A, Hovig T: Renal failure in familial lecithin-cholesterol acyltransferase deficiency. Nephron 18, 239-248 (1977).
10. Suzaki K, Kobori S, Ueno S et al.: Effects of plasmapheresis on familial Type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 80, 181-189 (1990).
11. Oikawa S, Matsunaga A, Saito T et al.: Apolipoprotein E sendai (arginine 145->proline): a new variant associated with lipoprotein glomerulopathy. J. Am. Soc. Nephrol. 8, 820-823 (1997).
12. Tolonen N, Forsblom C, Thorn L et al.: Lipid abnormalities predict progression of renal disease in patients with Type 1 diabetes. Diabetologia 52, 2522-2530 (2009).
13. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH: Microalbuminuria in Type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 60, 219-227 (2001).
14. Hadjadj S, Duly-Bouhanick B, Bekherraz A et al.: Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with Type 1 diabetes. Diabetes Metab. 30, 43-51 (2004).
15. Coonrod BA, Ellis D, Becker DJ et al.: Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 16, 1376-1383 (1993).
16. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group: Risk factors for renal dysfunction in Type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes 55, 1832-1839 (2006).
17. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE: Nephropathy in Type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int. 62, 963-970 (2002).
18. Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a renal risk factor in diabetic nephropathy? Am. J. Kidney Dis. 22, 196-201 (1993).
19. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348(5), 383-393 (2003).
20. Thorn LM, Forsblom C, Waden J et al.: The metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in Type 1 diabetes. Diabetes Care 32, 950-952 (2009).
21. Luk AO, So WY, Ma RC et al.: Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with Type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care 31, 2357-2361 (2008).
22. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int. 33, 917-924 (1988).
23. Nishida Y, Oda H, Yorioka N: Effect of lipoproteins on mesangial cell proliferation. Kidney Int. 56, S51-S53 (1999).
24. Rovin BH, Tan LC: LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int. 43, 218-225 (1993).
25. Lynn EG, Siow YL: Very low-density lipoprotein stimulates the expression of monocyte chemoattractant protein-1 in mesangial cells. Kidney Int. 57, 1472-1483 (2000).
26. Furuta T, Saito T, Ootaka T et al.: The role of macrophages in diabetic glomerulosclerosis. Am. J. Kidney Dis. 21, 480-485 (1993).
27. Vasconcelos EMA, Degasperi GR, de Oliveira HCF, Vercesi AE, de Faria EC, Castilho LN: Reactive oxygen species generation in peripheral blood monocytes and oxidized LDL are increased in hyperlipidemic patients. Clin. Biochem. 42, 1222-1227 (2009).
28. Keane WF, O'Donnell MP, Kasiske BL, Kim Y: Oxidative modification of low-density lipoproteins by mesangial cells. J. Am. Soc. Nephrol. 4, 187 (1993).
29. Ruan XZ, Varghese Z, Moorhead JF: An update on the lipid nephrotoxicity hypothesis. Nature Reviews Nephrology (2009).
30. Bussolati B, Deregibus MC, Fonsato V et al.: Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J. Am. Soc. Nephrol. 16(7), 1936-1947 (2005).
31. Dimmeler S, Haendeler J, Galle J, Zeiher AM: Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the 'response to injury' hypothesis. Circulation 95, 1760 (1997).
32. Sharma P, Reddy K, Franki N et al.: Native and oxidized low density lipoproteins modulate mesangial cell apoptosis. Kidney Int. 50, 1604-1611 (1996).
33. Keane WF: The role of lipids in renal disease: future challenges. Kidney Int. 57, S27-S31 (2000).
34. Zoja C, Corna D, Rottoli D et al.: Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 61, 1635-1645 (2002).
35. Misra A, Kumar S, Kishore Vikram N, Kumar A: The role of lipids in the development of diabetic microvascular complications: implications for therapy. Am. J. Cardiovasc. Drugs 3, 325-338 (2003).
36. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45, 485-493 (2005).
37. Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
38. Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR: Effects of long-term fenofibrate treatment on markers of renal function in Type 2 diabetes: FIELD Helsinki Substudy. Diabetes Care (2009).
39. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 59, 260-269 (2001).
40. Tonelli M, Isles C, Craven T et al.: Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112, 171-178 (2005).
41. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
42. Athyros VG, Mikhailidis DP, Papageorgiou AA et al.: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. BMJ 57, 728 (2004).
43. Shepherd J, Kastelein JJ, Bittner V et al.: Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study. Clin. J. Am. Soc. Nephrol. 2, 1131-1139 (2007).
44. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
45. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326, 1423-1427 (2003).
46. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH: Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 46, 1402-1407 (2003).
47. Stehouwer CDA, Gall MA, Twisk JWR, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in Type 2 diabetes. Diabetes 51, 1157-1165 (2002).
48. Shishehbor MH, Brennan ML, Aviles RJ et al.: Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108, 426-431 (2003).
49. Ridker PM, Danielson E, Fonseca FAH et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).